Literature DB >> 19604256

Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.

E G Rhee1, D H Barouch.   

Abstract

Innate immunity is critical for shaping vaccine-elicited adaptive immune responses. Several classes of immune sensors, including Toll-like receptors, retinoic acid-inducible gene-I-like receptors, nucleotide-binding oligomerization domain-like receptors and cytosolic DNA receptors mediate important innate immune pathways and provide potential targets for novel adjuvant development. Understanding how innate immunity modulates adaptive immune responses will probably be important for optimizing vaccine candidates. Here, we review recent advances in innate immunity, focusing upon their potential applications in developing adjuvants and vectors for HIV vaccines.

Mesh:

Substances:

Year:  2009        PMID: 19604256      PMCID: PMC2730842          DOI: 10.1111/j.1365-2249.2009.03928.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  77 in total

1.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

2.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 3.  Translating innate immunity into immunological memory: implications for vaccine development.

Authors:  Bali Pulendran; Rafi Ahmed
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

Review 4.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

5.  Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections.

Authors:  Judith N Mandl; Ashley P Barry; Thomas H Vanderford; Natalia Kozyr; Rahul Chavan; Sara Klucking; Franck J Barrat; Robert L Coffman; Silvija I Staprans; Mark B Feinberg
Journal:  Nat Med       Date:  2008-09-14       Impact factor: 53.440

6.  Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages.

Authors:  D M Underhill; A Ozinsky; K D Smith; A Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

7.  Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3.

Authors:  Thirumala-Devi Kanneganti; Nesrin Ozören; Mathilde Body-Malapel; Amal Amer; Jong-Hwan Park; Luigi Franchi; Joel Whitfield; Winfried Barchet; Marco Colonna; Peter Vandenabeele; John Bertin; Anthony Coyle; Ethan P Grant; Shizuo Akira; Gabriel Núñez
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

Review 8.  Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

Authors:  Jay T Evans; Christopher W Cluff; David A Johnson; Michael J Lacy; David H Persing; Jory R Baldridge
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

Review 9.  Challenges in the development of an HIV-1 vaccine.

Authors:  Dan H Barouch
Journal:  Nature       Date:  2008-10-02       Impact factor: 49.962

10.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.

Authors:  Stephanie C Eisenbarth; Oscar R Colegio; William O'Connor; Fayyaz S Sutterwala; Richard A Flavell
Journal:  Nature       Date:  2008-05-21       Impact factor: 49.962

View more
  5 in total

1.  What does the report of the USMHRP Phase III study in Thailand mean for HIV and for vaccine developers?

Authors:  Barney S Graham
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

2.  Multiple KIR gene polymorphisms are associated with plasma viral loads in SIV-infected rhesus macaques.

Authors:  Porntip Chaichompoo; Pavel Bostik; Susan Stephenson; Suthiphol Udompunturuk; Jaruda Kobkitjaroen; Kovit Pattanapanyasat; Aftab A Ansari
Journal:  Cell Immunol       Date:  2010-04-01       Impact factor: 4.868

Review 3.  Innate immunity against HIV: a priority target for HIV prevention research.

Authors:  Persephone Borrow; Robin J Shattock; Annapurna Vyakarnam
Journal:  Retrovirology       Date:  2010-10-11       Impact factor: 4.602

Review 4.  New concepts in HIV-1 vaccine development.

Authors:  Kathryn E Stephenson; Helen T D'Couto; Dan H Barouch
Journal:  Curr Opin Immunol       Date:  2016-06-03       Impact factor: 7.486

Review 5.  HIV-1 vaccine immunogen design strategies.

Authors:  Jaclyn K Mann; Thumbi Ndung'u
Journal:  Virol J       Date:  2015-01-24       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.